Download investment submission cover page

INVESTMENT SUBMISSION COVER PAGE
When submitting an investment opportunity to MABA, please first review our Investment Criteria
document – to ensure that there is a fit, and attach this cover page to your executive summary (which
should not exceed three pages).
Also, please be aware of MABA’s Presenting Company Warrant Grant Requirements:
MABA does not charge companies a cash fee to present. Nor does it get a free grant of equity.
In return for the opportunity to present to MABA, MABA receives from the company the chance to
invest in the company. While this chance may never have any value if the company is unable to achieve
its goals, should the company successfully accomplish what it has set out to do, the chance to invest
gives MABA the opportunity to benefit along with other investors.
Specifically, the company gives MABA the chance to invest up to $30,000 in the company, with the type
of security and the price MABA can buy determined by whatever investors accept in the next round.
MABA can take up to 7 years to make that investment. If MABA members do not invest at least
$125,000 in the company in the 12 month period following the company's presentation, MABA may
invest only up to $5,000 (but still for the type of security and at the price determined at the next round).
In reality, if the company is successful, a liquidity event would likely occur before the expiration of the 7
year time horizon, while chances are that the right may never be exercised and that it will have no value,
if the company does not succeed or there is no suitable liquidity event.
Please call us if you have any questions or concerns about this requirement. By submitting an
application, you acknowledge your acceptance of the terms noted above. Once we receive your
application, we will send you a Presenting Company Agreement. Qualified companies will only be
invited to present after we receive a signed copy of that agreement.
We look forward to receiving your submission.
1.
Name of company (plus website – if any)
2.
Name of main contact (name, title, phone(s) & email)
3.
Location of company (if virtual, location of main
contact)
4.
Amount of money previously raised (total)
5.
Start-up date
6.
Date last round closed
7.
Post-money valuation at the last round
8.
Amount of money being raised in current round
9.
Pre-money valuation for current round
10. Date current round began & amount of money
invested so far
11. Including the current round, how much more
investment capital will be required (including all
future rounds and not including grants or other nondilutive funding)?
12. What event will render further funding unnecessary
(e.g., licensing deal, breakeven achieved, other)?
13. Describe non-dilutive or grant funding already
received or applied for (please differentiate between
received and applied for)
14. Describe the company’s product or service (one
sentence)
15. What is the market need for the company’s
product/service (one sentence)?
16. Is this a single product/service or a platform?
17. If the company has developed a platform, what is
the first product/service to be marketed
commercially?
18. What is/are your main competitive advantage(s)?
19. Please identify your major competitors.
20. If already selling – annual $ sales and number of
customers
21. Total addressable market (if platform – for first
product only)
22. Current development stage (of first product/service)
23. Sales and Go-to-Market Strategy
24. Describe status and scope of patent protection, if any
(number of applications, nature of claims, when
filed/granted)
25. Is there other IP – that might affect the
product/service?
26. Who owns the patents and other IP, if any?
27. Describe competitive IP landscape and how the
company’s IP fits within that landscape
28. Briefly describe how product/device will be
manufactured
29. Current & anticipated alliance partners (specifics)
30. FDA strategy, time to approval of primary
indication/first product and approval pathway
31. Time to reach major inflection point (in question 12)
32. Describe major inflection point – in words and $s
(e.g., exit, license…)
33. Key beneficiary(ies) (in addition to patients, who
benefits the most – financially and otherwise – from
your product/service, e.g., hospitals – if product
reduces/eliminates hospital never events)
34. Reimbursement strategy (one sentence)
35. Management team (P&L/operating experience,
significant accomplishments, prior fundraising
experience and return to investors (If any))
36. Endorsement(s)/key supporters/key opinion leaders
(specific names)
37. Professional advisors (specific names) (legal,
accounting, regulatory consultants, others?)
38. Please indicate at least one significant publication
that you believe supports your technology. (Be
specific. If possible, please attach to submission)
39. Describe all special deals and circumstances with and
between partners, related parties and anyone else
(grant backs to founders, special licenses, etc.)
40. How can investors lose their money? What are the
biggest risks (competitive, regulatory, technical, etc.)
standing between the company and successful
commercialization and exit?
41. Current salary and other compensation for each
executive. How will it change after financing?
42. Are any of the team members related to one another
(if so, how)?
43. Anticipated use of funds from this point forward
44. How did you hear of MABA?
Please return this completed document - with your company name incorporated into the document
name, along with an executive summary, to [email protected]
Thank you.
Mid Atlantic Bio Angels (MABA)